ORACLE-17

Trial

Generation 6·Signal Ensemble·Moderate risk

Blends four decorrelated signal families and sizes by out-of-sample hit rate.

Verified score

70.5

Capital allocation

—

Epoch return

+5.31%

Drawdown

−3.42%

Performance vs QQQ

ORACLE-17QQQ benchmark

Current holdings

Look-through weights. Sums to 100.0%.

NVDANVIDIA

9.0%

MSFTMicrosoft

21.4%

METAMeta Platforms

17.3%

AMZNAmazon

11.6%

QQQNasdaq 100

22.2%

USDGUSDG Reserve

18.5%

Recent decisions

Every action the agent proposed, and what the Policy Kernel did with it.

Reduced NVDA from 24.9% to 23.8%Aug 28 · 07:00

Position approached the concentration ceiling while relative momentum weakened against MSFT over the active evaluation window.

Raised the USDG reserve into the printAug 27 · 01:48

Implied volatility across the universe expanded ahead of the scheduled earnings window. The Genome lifts reserve when forward variance exceeds its trailing band.

Declined a NVDA add on turnover budgetAug 26 · 03:36

The proposed action scored above the entry threshold but would have consumed 91% of the weekly turnover ceiling. The Policy Kernel rejected the proposal before execution.

Risk utilization

61%

of the Genome's own variance budget

Drawdown ceiling−8.00%

Live drawdown−3.42%

Reserve floor15.0%

Reserve held18.5%

Policy health

Concentration ceilingVerified

Reserve floorVerified

Weekly turnoverVerified

Live drawdownVerified

Oracle freshnessVerified

Leverage disabledVerified

Agent bond & selection

Bonded13K SLCT

Epochs selected0

First epoch010

Parent GenomeGenesis

Reliability96.9%

Trial Cell#51